Quercetin for Hypertension

Verdict: Modest, dose-dependent blood-pressure benefit

Quercetin appears to produce a small but consistent reduction in blood pressure, on the order of 2-3 mmHg, mainly at doses of 500 mg/day or higher and in people who are already pre-hypertensive or hypertensive. It is not a substitute for proven first-line measures, and its long-term effect on actual cardiovascular events is unknown.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

Four independent meta-analyses pooling roughly 590 to 900 participants point the same direction. The two largest (PMID 31940027, n=896 across 17 trials; PMID 35948195, n=841) found systolic reductions of about 2.4 to 3.1 mmHg, an earlier review (PMID 27405810, n=587) reported -3.04 mmHg systolic and -2.63 mmHg diastolic, and a metabolic-syndrome analysis (PMID 31092175) still showed a significant -1.69 mmHg systolic. This agreement across separate datasets is what lifts the claim above weak/exploratory evidence.

The grade stays at preliminary rather than higher because the effect is small and its real-world importance is unproven. Benefit clusters at doses of 500 mg/day and above, so lower-dose products may do little; diastolic results are inconsistent and non-significant in the metabolic-syndrome group (PMID 31092175); the trials are heterogeneous; and funding for most reviews is undisclosed, so industry bias cannot be ruled out. No trial has tested whether quercetin prevents strokes or heart attacks.

Authorities are cautious to unsupportive. EU EFSA rejected quercetin's cardiovascular health claims for lack of an established cause-and-effect relationship; the US FDA treats it as a food ingredient (GRAS) but has warned companies against disease claims; and the WHO/IARC statement only addresses carcinogenicity (Group 3), not blood pressure. Mayo, Cleveland Clinic and Harvard do not endorse it as a supplement for hypertension, and no major guideline recommends it over diet, exercise, or medication.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.61
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
76%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.70
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.61
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 27405810 2016 統合分析 n = 587
Finding: Quercetin significantly reduced SBP (WMD -3.04 mmHg, 95% CI -5.75 to -0.33, p=0.028) and DBP (WMD -2.63 mmHg, 95% CI -3.26 to -2.01, p<0.001); effect driven by doses ≥500 mg/day.
Effect size: WMD SBP -3.04 mmHg; DBP -2.63 mmHg
View on PubMed
Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis
PMID: 31940027 2020 統合分析 n = 896
Finding: Quercetin significantly reduced SBP (WMD -3.09 mmHg, 95% CI -4.59 to -1.59, p=0.0001) and DBP (WMD -2.86 mmHg, 95% CI -5.09 to -0.63, p=0.01) across 17 RCTs.
Effect size: WMD SBP -3.09 mmHg; DBP -2.86 mmHg
View on PubMed
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
PMID: 35948195 2022 統合分析 n = 841
Finding: Quercetin reduced SBP -2.38 mmHg (p=0.01) in mixed population and DBP -3.14 mmHg in (pre)hypertensive subgroup (p<0.00001); normotensive SBP reduction also significant (p<0.0001).
Effect size: MD SBP -2.38 mmHg (mixed); DBP -3.14 mmHg (pre-hypertensive)
View on PubMed
The Effects of Quercetin Supplementation on Blood Pressures and Endothelial Function Among Patients with Metabolic Syndrome and Related Disorders
PMID: 31092175 2019 統合分析
Finding: Quercetin significantly reduced SBP (WMD -1.69 mmHg, 95% CI -3.22 to -0.17) but not DBP (WMD -3.14, 95% CI -8.24 to 1.95) in metabolic syndrome patients across 8 RCTs.
Government Effect size: WMD SBP -1.69 mmHg; DBP NS
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA has no questions; some uses may require a color additive listing source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
洋蔥萃取物原料係由洋蔥(Allium cepa)之鱗莖,經萃取製得。前點製得之洋蔥萃取物原料,其每日食用限量,以槲皮素(quercetin)計為1000毫克。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Neutral
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-hypertension-INT-quercetin-001 繁體中文版 →